Repligen | RGEN - L'Utile Ante Imposte





L'Utile Ante Imposte Cambiamento Data
Agilent USD 364M 78M 2025-12
Align Technology USD 148.89M 27.71M 2026-03
Bio Techne USD 50.78M 34.21M 2025-12
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Bruker USD 68.2M 140.8M 2025-12
Charles River Laboratories USD -294.1M 464.13M 2025-12
Danaher USD 1.24B 138M 2026-03
Dentsply International USD -42M 105M 2026-03
General Electric Aerospace USD 2.2B 654M 2026-03
Henry Schein USD 150M 17M 2026-03
Illumina USD 157M 220M 2026-03
IQVIA Holdings USD 6.22B 5.68B 2026-03
Mettler Toledo International USD 329.07M 59.84M 2025-12
Myriad Genetics USD 4.6M 3.4M 2025-12
OraSure Technologies USD -18.43M 5.14M 2025-12
Pacific Biosciences Of California USD -40.17M 2.55M 2025-12
Pfizer USD 5.18B 6.82B 2026-03
Repligen USD 19.11M 2M 2025-12
Revvity USD 91.56M 35.88M 2025-12
Standard Biotools USD -22.03M 10.87M 2025-12
Thermo Fisher Scientific USD 2.12B 295M 2025-12
Waters USD 264.18M 94.06M 2025-12
West Pharmaceutical Services USD 161.5M 8.6M 2025-12